Using a novel macrocyclic inhibitor of cyclin/CDK (CIR7–2512) or the CDK2 inhibitor tagtociclib, we demonstrated in vitro activity in PRAD that was comparable to EZH2 inhibition. The gene discussed is EZH2; the disease is prostate adenocarcinoma.